<SEC-DOCUMENT>0001193125-24-171192.txt : 20240628
<SEC-HEADER>0001193125-24-171192.hdr.sgml : 20240628
<ACCEPTANCE-DATETIME>20240628063257
ACCESSION NUMBER:		0001193125-24-171192
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240627
FILED AS OF DATE:		20240628
DATE AS OF CHANGE:		20240628

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		241081275

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d798849d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as June 27, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d798849dex991.htm">Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June 27, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d798849dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g798849g23o94.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Reports Positive Topline
Results from <FONT STYLE="white-space:nowrap">TACTI-003</FONT> Phase IIb Trial in First Line Head and Neck Cancer </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efti in combination with KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) in
first line head and neck squamous cell carcinoma (1L HNSCC) led to overall response rates that exceed KEYTRUDA monotherapy across all levels of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In the randomised, controlled Cohort A, the combination shows the strongest performance in patients with high <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression (CPS <U>&gt;</U>20) with an overall response rate (ORR) of 31.0% as compared to 18.5% for KEYTRUDA monotherapy </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In patients with negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (CPS &lt;1, Cohort B), a
patient population with no effective chemotherapy-free options, the response rate has substantially improved from the preliminary 26.9% ORR reported in April and topline results with additional data has been accepted for oral presentation at an ESMO
Virtual Plenary session on 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> July </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Additional clinical data from <FONT STYLE="white-space:nowrap">TACTI-003</FONT> will be presented at a medical
conference in H2 CY2024 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Based on the positive topline results, the Company will discuss the path forward in 1L HNSCC with regulatory
agencies </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Immutep to host webcast to discuss clinical data today at 9AM AEST (7PM ET, Wednesday 26 June)
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; June</B><B></B><B>&nbsp;27, 2024 &#150;</B> Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148;
or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces topline results from the <FONT
STYLE="white-space:nowrap">TACTI-003</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(KEYNOTE-PNC-34)</FONT></FONT> Phase IIb trial evaluating eftilagimod alfa (efti) in combination with MSD&#146;s (Merck&nbsp;&amp; Co.,
Inc., Rahway, NJ, USA) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) as first-line treatment of
recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC). The trial enrolled 171 patients with any <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (Combined Positive Score [CPS] &#8805;1) and negative <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression (CPS &lt;1) at over 30 centres across the United States, Europe, and Australia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Topline Results
&#150; overall trial, primary endpoint </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s MHC Class&nbsp;II agonist in combination with KEYTRUDA led to higher overall response rates in
evaluable patients according to RECIST 1.1 &#150; the primary endpoint of the study &#150; across all levels of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (CPS <U>&gt;</U>20, CPS <FONT STYLE="white-space:nowrap">1-19,</FONT> CPS
<U>&gt;</U>1, CPS &lt;1) as compared to KEYTRUDA monotherapy (see Table 1). In the overall evaluable <FONT STYLE="white-space:nowrap">TACTI-003</FONT> patient population (Cohort A and B), the response rate for efti in combination with KEYTRUDA was
~34% regardless of HPV status and <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, including patients with negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Martin Forster of the UCL Cancer Institute and University College London Hospital NHS Foundation, London, UK, and
<FONT STYLE="white-space:nowrap">TACTI-003</FONT> Investigator, stated, &#147;It is encouraging to see efti safely drive higher response rates in combination with KEYTRUDA in the first line setting for head and neck squamous cell carcinoma patients,
regardless of HPV status and levels of <FONT STYLE="white-space:nowrap">PD-L1.</FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g798849g23o94.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The strong, consistent response rates, irrespective
of whether patients have high, low, or negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, is intriguing and offers a glimpse into this novel combination&#146;s ability to improve patients&#146; clinical responses and expand patient
populations that benefit from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cohort A
results &#150; randomised part of trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the randomised, controlled Cohort A (N=138; thereof 118 evaluable) comprised of 1L HNSCC patients with any <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression (CPS <U>&gt;</U>1), the novel immuno-oncology (IO) combination shows the strongest outperformance in patients with high <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (CPS <U>&gt;</U>20)
with a 31.0% overall response rate (ORR) and 75.9% disease control rate (DCR) in evaluable patients (N=29) as compared to a 18.5% ORR and 59.3% DCR for KEYTRUDA monotherapy in evaluable patients (N=27). High
<FONT STYLE="white-space:nowrap">PD-L1</FONT> expressing patients represent ~50% of the overall population in 1L HNSCC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The IO combination also achieved
a relatively high ORR of 34.5% in evaluable patients (N=29) with low <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (CPS <FONT STYLE="white-space:nowrap">1-19).</FONT> The ORR with KEYTRUDA monotherapy in patients with low <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression in <FONT STYLE="white-space:nowrap">TACTI-003</FONT> (N=33) was 33.3% and is higher than historical published data for pembrolizumab monotherapy, including a 14.5% ORR in patients with CPS <FONT
STYLE="white-space:nowrap">1-19</FONT> in a registrational study<SUP STYLE="font-size:75%; vertical-align:top">1</SUP>. The large difference of the control arm versus historical results in low <FONT STYLE="white-space:nowrap">PD-L1</FONT> patients
may be explained by imbalances between the <FONT STYLE="white-space:nowrap">TACTI-003</FONT> treatment groups, including smoker status and location of primary tumour. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cohort B results </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is also pleased to report
that the response rate in patients with negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (CPS &lt;1) in Cohort B has substantially improved from the preliminary 26.9% ORR reported in April and that the updated clinical data has been
accepted for an ESMO Virtual Plenary session. ESMO Virtual Plenaries are monthly presentations of the latest, original scientific data, including <I>&#147;Phase II trials which</I> <I>demonstrate remarkable therapeutic benefit, scientific insight or
progress in an area of unmet need&#148;.</I> Final topline results including complete response rate in patients with negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, who represent ~20% of the overall population in 1L HNSCC, will be
delivered via an oral presentation on 11&nbsp;July 2024. This cohort was not randomised due to ethical reasons as KEYTRUDA monotherapy is not approved for these patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Table 1: ORR in Evaluable Patients according to RECIST 1.1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="white-space:nowrap">TACTI-003</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Efti&nbsp;+&nbsp;KEYTRUDA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">KEYTRUDA&nbsp;monotherapy</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">High <FONT STYLE="white-space:nowrap">PD-L1</FONT> Expression (CPS &#8805;20)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31.0%&nbsp;ORR&nbsp;(N=29)&#8196;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">18.5%&nbsp;ORR&nbsp;(N=27)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Low <FONT STYLE="white-space:nowrap">PD-L1</FONT> Expression (CPS
<FONT STYLE="white-space:nowrap">1-19)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34.5%&nbsp;ORR&nbsp;(N=29)&#8196;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">33.3% ORR (N=33)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Any <FONT STYLE="white-space:nowrap">PD-L1</FONT> Expression (CPS &#8805;1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32.8%&nbsp;ORR&nbsp;(N=58)&#8196;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">26.7% ORR (N=60)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> Expression (CPS &lt;1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">26.9%&nbsp;ORR&nbsp;(N=26)<SUP STYLE="font-size:75%; vertical-align:top">2</SUP></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">N/A</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safety </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to
safety, the profile of efti in combination with KEYTRUDA continues to be favourable with no new safety signals as expected. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g798849g23o94.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Fr&eacute;d&eacute;ric Triebel, CSO of
Immutep, said: &#147;We are pleased with the quality of responses. Once again, durability is tracking well driven by the complementary nature of these two unique immunotherapies in fighting cancer. Efti&#146;s distinct activation of dendritic cells
as an MHC Class&nbsp;II agonist and the resulting engagement of multiple facets of the adaptive&nbsp;&amp; innate immune system has consistently translated into promising duration of responses in combination with immune checkpoint inhibitors across
multiple oncology indications. From a statistical point of view, given the relatively small number of evaluable patients and the very ambitious differences required to generate significance, coupled with unexpected imbalances leading to
unanticipated strength in the control arm among patients with low <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, we are excited to see the ~68% differential in the largest patient segment (CPS <U>&gt;</U>20) in 1L HNSCC in a randomised
setting.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Additionally, the strength of clinical results in patients with negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression is
notable, and we look forward to sharing more data at the ESMO Virtual Plenary session in July,&#148; added Dr.&nbsp;Triebel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Next Steps </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on these positive topline results, the Company will discuss potential options with regulatory agencies for metastatic 1L HNSCC patients. More detailed
clinical data from <FONT STYLE="white-space:nowrap">TACTI-003</FONT> will be presented at a medical conference in H2 CY2024.&#8195; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call
and Webcast Details </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep will host a conference call and webcast to discuss the clinical data. The event will feature CEO Marc Voigt, CSO Dr
Frederic Triebel, CMO Dr Florian Vogl, and Christian Mueller, Senior Vice President Strategic Development. An open question&nbsp;&amp; answer session with all presenters will conclude the event. A replay of the webcast will be available under the
Events section of Immutep&#146;s website. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date/Time: Thursday, 27&nbsp;June, at 9AM AEST (Wednesday, June&nbsp;26, at 7PM ET) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Register: Link to register for webcast </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Questions: Investors are invited to submit questions in advance via immutep@morrowsodali.com
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti has received FDA Fast Track designation in 1L HNSCC regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of
Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the <FONT STYLE="white-space:nowrap">TACTI-003</FONT> Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">TACTI-003</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(KEYNOTE-PNC-34)</FONT></FONT> trial is
an ongoing Phase IIb study evaluating eftilagimod alfa (efti), Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist, in combination with MSD&#146;s <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) as first line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The
randomized Cohort A portion of the study is evaluating efti in combination with pembrolizumab as compared to pembrolizumab monotherapy in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> positive (Combined Positive Score [CPS] &#8805;1)
tumours, whereas Cohort B is evaluating efti in combination with pembrolizumab in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative tumours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary endpoint of the study is Overall Response Rate of evaluable patients according to RECIST 1.1. Secondary endpoints include Overall Survival,
Overall Response Rate according to iRECIST, Progression Free Survival, and Duration of Response. For more information about the Phase IIb trial, visit clinicaltrials.gov (NCT04811027). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g798849g23o94.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alfa (Efti) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and
adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex)
Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT
STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy
and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>1. Source: Burtness, B. et al. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in <FONT
STYLE="white-space:nowrap">KEYNOTE-048:</FONT> Subgroup Analysis by Programmed Death <FONT STYLE="white-space:nowrap">Ligand-1</FONT> Combined Positive Score. Journal of Clinical Oncology 2022 40:21, 2321-2332 </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2. In patients with negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (CPS &lt;1), the 26.9% ORR in evaluable patients from efti in
combination with pembrolizumab is the preliminary response rate reported in April 2024. The ORR has improved substantially and will be updated at ESMO Virtual Plenary session in July. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Morrow
Sodali </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; c.strong@morrowsodali.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; chris.basta@immutep.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g798849g23o94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g798849g23o94.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MRJ.O)58U?:.7/94V[3YM='&.^UD?HM7U!^J[>5@H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M\&?B'/\ $3PF;[4$BCUK2[IM-U;R%\N&>58HYH+V*+)\I9H) 2@.%DCD"X7
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MO+*POFT^XFN?&T^C(MXMO#=&&&TAN(^!#<0G<L:IE\9R#@_0/T--?BG^T7\
MO$=G8>.;G5=3LI@)?[*\37B:UIVJV<;JLYTC7XY)I()D# 9BG/ELR>="0P5C
M8-C],? OC+2/'_A31?%VALQT_6+43I%+M$]I<1NT-W8W*J2%N+>ZCEA?'!,>
MY<JP) V^1UN,?Y]*-OD&WR#I[8_#&* V\K!0 4 % !0 4 % !0 4 % !0 4
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MQ%_[ T'_ *=-/H ^;/V$/^/;XG?]?/A/_P!$Z]0!X9XD_P"3NG]OC!H7X?\
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M] _0S?V(;NYF^&.OVDI8VUCXSO5M,]$6XTK29YHT/]WSF+X]9">] 'V90 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MPH51P    !0!Q'B3X9_#[Q?-]I\3^#?#NM70 'VR^TNUDO2JC"J;P1B9E '
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MZ_EC&+NYN) ^W>#*V& .* ,/PYJ?BN:W^$!U,6<=IJ%K&US<VVM:A>WNIL?
MNIW<9U.WN-*MT)::-;AR;B?;-&I&[&\ $O@FZ2X\1ZT]Y?Z=+=Q^*?&5K;QR
M^,M5GU<16VLW\%M:_P#"*R@6<5O%9QX38S%8XDD502=H!B:!=:NOB#1;B?\
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M>&O;&-3CH X[]AW_ ))SXJ]O&LWX8T/1: /M2@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ,=NW3'_UJ *T=E9P[
MA#:VT.[;O\J"*/=L.Y-VU!G:W(ST/(H G**6#%1N7.UB!N7( ;:>HR  <>E
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M.'W_ #9'.>>M !Y<>PQ[$V-NW)M&T[B2VY<8.XDD\<Y.>M "JBH254*6QN(
M!.T8&2.N!P,T !52RL5&Y<[6(&5R,'![9 &<>E #)8(9UV311RH"#LE173*]
M#M<$9'K0 0P06ZE((8H%)W%88TC4M@#)5 !G  S[4 2T % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M!_PK[XP?]"WXW_+4/_CU'U7'?\^JO_DW^8?V7GW_ $"8O[Y__)!_PK[XP?\
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MO[Y__)!_PK[XP?\ 0M^-_P M0_\ CU'U7'?\^JO_ )-_F']EY]_T"8O[Y_\
MR0?\*^^,'_0M^-_RU#_X]1]5QW_/JK_Y-_F']EY]_P! F+^^?_R0?\*^^,'_
M $+?C?\ +4/_ (]1]5QW_/JK_P"3?YA_9>??] F+^^?_ ,D'_"OOC!_T+?C?
M\M0_^/4?5<=_SZJ_^3?YA_9>??\ 0)B_OG_\D'_"OOC!_P!"WXW_ "U#_P"/
M4?5<=_SZJ_\ DW^8?V7GW_0)B_OG_P#)!_PK[XP?]"WXW_+4/_CU'U7'?\^J
MO_DW^8?V7GW_ $"8O[Y__)!_PK[XP?\ 0M^-_P M0_\ CU'U7'?\^JO_ )-_
MF']EY]_T"8O[Y_\ R0?\*^^,'_0M^-_RU#_X]1]5QW_/JK_Y-_F']EY]_P!
MF+^^?_R0?\*^^,'_ $+?C?\ +4/_ (]1]5QW_/JK_P"3?YA_9>??] F+^^?_
M ,D'_"OOC!_T+?C?\M0_^/4?5<=_SZJ_^3?YA_9>??\ 0)B_OG_\D'_"OOC!
M_P!"WXW_ "U#_P"/4?5<=_SZJ_\ DW^8?V7GW_0)B_OG_P#)!_PK[XP?]"WX
MW_+4/_CU'U7'?\^JO_DW^8?V7GW_ $"8O[Y__)!_PK[XP?\ 0M^-_P M0_\
MCU'U7'?\^JO_ )-_F']EY]_T"8O[Y_\ R0?\*^^,'_0M^-_RU#_X]1]5QW_/
MJK_Y-_F']EY]_P! F+^^?_R0?\*^^,'_ $+?C?\ +4/_ (]1]5QW_/JK_P"3
M?YA_9>??] F+^^?_ ,D'_"OOC!_T+?C?\M0_^/4?5<=_SZJ_^3?YA_9>??\
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MSZJ_^3?YA_9>??\ 0)B_OG_\D'_"OOC!_P!"WXW_ "U#_P"/4?5<=_SZJ_\
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M'_0M^-_RU#_X]1]5QW_/JK_Y-_F']EY]_P! F+^^?_R0?\*^^,'_ $+?C?\
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M/_CU'U7'?\^JO_DW^8?V7GW_ $"8O[Y__)'Z@8'I7UI^PV78,#TH"R[!@>E
M678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E
M678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E
M678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E
M678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E
M678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E
M678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E
M678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E
M678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E
M678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E
M678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E
M678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E
M678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E 678,#TH"R[!@>E
6678,#TH"R[!@>E 678,#TH"R['__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
